Evidence Snapshot

Serotonin 2 (5-HT2) receptor

CHEMBL2095200 PROTEIN FAMILY Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:25:53Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 6:25 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL2095200

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Serotonin 2 (5-HT2) receptor as ChEMBL target CHEMBL2095200, mapped to UniProt P41595. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Serotonin 2 (5-HT2) receptor

PROTEIN FAMILY · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL2095200

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P41595

5-hydroxytryptamine receptor 2B

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Serotonin 2 (5-HT2) receptor matters

As of 2026-09-13

Serotonin 2 (5-HT2) receptor is reviewed as 5-hydroxytryptamine receptor 2B (UniProt P41595); Serotonin 2 (5-HT2) receptor shows approved-linked disease relevance led by major depressive disorder. 1 more disease program remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 6 approved drugs, 235 compounds, and 66 assays, with lead potency reaching pChEMBL 9.3.

Protein context

5-hydroxytryptamine receptor 2B

5-hydroxytryptamine receptor 2B Sequence length is 481 aa.

Review this target as Serotonin 2 (5-HT2) receptor, mapped to UniProt P41595. ChEMBL maps the protein component as 5-hydroxytryptamine receptor 2B. Sequence length is 481 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P41595 Protein

Disease context

major depressive disorder

Serotonin 2 (5-HT2) receptor shows approved-linked disease relevance led by major depressive disorder. 1 more disease program remain visible in the same review block. 1 linked drug keep the rationale reviewable. 1 additional disease programs remain visible in the same card. Linked drugs include MINAPRINE.

Start review with major depressive disorder because it currently carries approved-linked support. Linked drugs include MINAPRINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 1 linked drug

Activity base

Portfolio and assay base

ChEMBL currently tracks 6 approved drugs, 235 compounds, and 66 assays for this target. The dominant activity type is KI. CHEMBL5204619 is the current potency anchor at pChEMBL 9.3.

Use CHEMBL5204619 as the tractability anchor when discussing potency (pChEMBL 9.3).

Activity source · ChEMBL 36 via Core Engine

6 approved pChEMBL 9.3

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Serotonin 2 (5-HT2) receptor matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P41595, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why major depressive disorder is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

235

Total Compounds

Total Assays

Approved Drugs

IC50: 50.0, KI: 158.0, KD: 1.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL5204619	9.3	Ki	—
No preferred name CHEMBL45491	9.2	Ki	—
No preferred name CHEMBL300647	9.0	Ki	—
No preferred name CHEMBL257704	8.9	Kd	Clinical
No preferred name CHEMBL1423	8.6	IC50	Approved